
Global Inhalation Anaesthesia Market Report and Forecast 2024-2032
Description
Global Inhalation Anaesthesia Market Report and Forecast 2024-2032
Global Inhalation Anaesthesia Market Report and Forecast 2024-2032
The global inhalation anaesthesia market size reached a value of more than USD 1.25 billion in 2023 driven by the increasing prevalence of chronic diseases and medical device manufacturers across the globe. The market is further estimated to grow at a CAGR of 9.40% in the forecast period of 2024-2032 and attain a market value of USD 2.81 billion by 2032.
Global Inhalation Anaesthesia Market Analysis
Inhalation anaesthesia is a critical component in modern surgical procedures, offering controlled and effective sedation for patients. It involves the administration of anaesthetic gases, such as sevoflurane, desflurane, and isoflurane, which induce and maintain anaesthesia during surgery. The global inhalation anaesthesia market has experienced substantial growth over recent years, driven by advancements in healthcare infrastructure, increasing surgical procedures, and rising awareness about the benefits of inhalation anaesthetics.
Market Drivers
1. Increasing Surgical Procedures
The global rise in surgical procedures, particularly in emerging economies, is a significant driver for the inhalation anaesthesia market. The prevalence of chronic diseases and conditions requiring surgery, such as cardiovascular diseases, cancer, and neurological disorders, is contributing to the increased demand for anaesthetic agents.
2. Advancements in Anaesthetic Technologies
Technological advancements in anaesthetic delivery systems have improved the safety and efficacy of inhalation anaesthesia. Modern anaesthetic machines offer precise control over the dosage and delivery of anaesthetic gases, reducing the risk of complications and enhancing patient outcomes.
3. Rising Geriatric Population
The ageing global population is another key factor driving the market. Older adults are more likely to undergo surgical procedures due to age-related health issues, thereby increasing the demand for effective anaesthetic solutions.
4. Enhanced Awareness and Training
Improved training for anaesthesiologists and heightened awareness about the benefits of inhalation anaesthesia over intravenous anaesthesia in specific situations have contributed to market growth. Inhalation anaesthetics are often preferred for their rapid onset and ease of administration.
Challenges
1. High Costs and Limited Accessibility
Despite the benefits, the high costs associated with inhalation anaesthetics and anaesthetic equipment can be a barrier, particularly in low-income regions. Limited accessibility to advanced healthcare facilities and trained professionals in these areas further hinders market expansion.
2. Environmental Concerns
Inhalation anaesthetics, particularly desflurane and nitrous oxide, are potent greenhouse gases. Their use contributes to environmental pollution and climate change, leading to increased scrutiny and regulatory pressures. The environmental impact of these gases is a growing concern, necessitating the development of more eco-friendly alternatives.
3. Potential Side Effects
While generally safe, inhalation anaesthetics can cause side effects such as nausea, vomiting, and, in rare cases, malignant hyperthermia. These potential adverse effects can limit their use and acceptance among patients and healthcare providers.
Future Opportunities
1. Development of Eco-friendly Anaesthetics
There is a significant opportunity for the development and adoption of eco-friendly inhalation anaesthetics. Research and innovation in this area could mitigate environmental concerns and meet the growing demand for sustainable medical practices.
2. Expansion in Emerging Markets
Emerging markets, particularly in Asia-Pacific and Latin America, present substantial growth opportunities. Increasing investments in healthcare infrastructure, coupled with rising disposable incomes, are likely to drive the demand for advanced anaesthetic solutions in these regions.
3. Integration of AI and Machine Learning
The integration of artificial intelligence (AI) and machine learning in anaesthetic delivery systems can revolutionise the market. AI-powered anaesthetic machines can provide real-time monitoring and adjustments, ensuring optimal anaesthesia levels and enhancing patient safety.
4. Personalised Anaesthesia
Advancements in personalised medicine offer the potential for tailored anaesthetic regimens based on individual patient profiles. This approach can improve efficacy, reduce side effects, and enhance overall patient satisfaction.
Global Inhalation Anaesthesia Market Trends
The global inhalation anaesthesia market is experiencing dynamic shifts driven by technological advancements and evolving healthcare demands. Here are some of the most insightful trends shaping this market:
1. Adoption of Low-flow Anaesthesia Techniques
There is an increasing trend towards the adoption of low-flow anaesthesia techniques. These methods reduce the consumption of anaesthetic gases, leading to cost savings and a lesser environmental impact. This trend is supported by advancements in anaesthesia machines that allow precise control over gas flow rates.
2. Rising Popularity of Sevoflurane
Sevoflurane is gaining popularity due to its favourable pharmacokinetic properties, such as rapid induction and recovery times. It is increasingly preferred over other inhalation anaesthetics for both adult and paediatric surgeries. The growing use of sevoflurane is enhancing patient throughput and efficiency in operating rooms.
3. Integration of Artificial Intelligence in Anaesthesia Management
The integration of artificial intelligence (AI) in anaesthesia management systems is a notable trend. AI algorithms are being developed to assist anaesthesiologists in monitoring patient vitals and adjusting anaesthetic dosages in real-time. This technology enhances precision, reduces human error, and improves patient safety.
4. Shift Towards Environmentally Sustainable Practices
Environmental sustainability is becoming a crucial consideration in the inhalation anaesthesia market. There is a growing emphasis on developing and using eco-friendly anaesthetic agents with lower global warming potential. Manufacturers are also focusing on recycling and proper disposal practices to minimise the environmental impact.
5. Increased Focus on Training and Education
There is a heightened focus on the training and education of anaesthesiologists and healthcare professionals. Comprehensive training programs on the latest anaesthetic techniques and technologies are being implemented globally. This trend ensures that healthcare providers are well-equipped to deliver safe and effective anaesthesia care.
6. Expansion of Ambulatory Surgery Centres
The expansion of ambulatory surgery centres (ASCs) is influencing the demand for inhalation anaesthetics. ASCs offer same-day surgical care, and the convenience of inhalation anaesthesia, with its rapid induction and recovery, makes it ideal for these settings. This trend is driving market growth, particularly in urban areas with increasing outpatient procedures.
7. Technological Advancements in Anaesthetic Delivery Systems
Technological advancements in anaesthetic delivery systems are transforming the market. Modern anaesthesia machines are equipped with features such as automated control of anaesthetic depth, integrated patient monitoring, and enhanced safety mechanisms. These innovations are improving the efficacy and safety of inhalation anaesthesia.
Global Inhalation Anaesthesia Market Segmentation
Market Breakup by Drug Type
- Sevoflurane
- Desflurane
- Isoflurane
- Halothane
Market Breakup by Application
- Induction
- Maintenance
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Inhalation Anaesthesia Market Competitive Landscape
The competitive landscape of the inhalation anaesthesia market features key players such as Halocarbon Life Sciences, LLC, Baxter International Inc, AbbVie Inc., Sandoz AG, Piramal Enterprises Ltd., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd. Common market activities include mergers and acquisitions to expand market reach and capabilities, extensive research initiatives to develop advanced anaesthetic agents, frequent product introductions to meet evolving healthcare needs, and strategic partnerships to enhance distribution networks and technological advancements. These activities collectively drive innovation, improve patient outcomes, and strengthen market positions, contributing to the dynamic and competitive nature of the inhalation anaesthesia market.
Key Questions Answered in the Report
- What is the current and future performance of the inhalation anaesthesia market?
- What are the main challenges facing the inhalation anaesthesia market?
- What are the key drivers of the inhalation anaesthesia market?
- What emerging trends are shaping the future of the inhalation anaesthesia market?
- How have technological advancements in anaesthetic delivery systems improved the safety of inhalation anaesthesia?
- How has improved training for anaesthesiologists influenced the market growth of inhalation anaesthesia?
- How is the inhalation anaesthesia market addressing environmental sustainability concerns?
- What factors are driving the growth of the inhalation anaesthesia market in Asia Pacific and Latin America?
- What are the common strategies used by key players in the inhalation anaesthesia market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global inhalation anaesthesia market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global inhalation anaesthesia market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global inhalation anaesthesia industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Inhalation Anaesthesia Market Overview
- 3.1 Global Inhalation Anaesthesia Market Historical Value (2017-2023)
- 3.2 Global Inhalation Anaesthesia Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Inhalation Anaesthesia Market Landscape*
- 5.1 Global Inhalation Anaesthesia: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Inhalation Anaesthesia: Product Landscape
- 5.2.1 Analysis by Drug Type
- 5.2.2 Analysis by Application
- 6 Global Inhalation Anaesthesia Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Inhalation Anaesthesia Market Segmentation (2017-2032)
- 7.1 Global Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 7.1.1 Market Overview
- 7.1.2 Sevoflurane
- 7.1.3 Desflurane
- 7.1.4 Isoflurane
- 7.1.5 Halothane
- 7.2 Global Inhalation Anaesthesia Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Induction
- 7.2.3 Maintenance
- 7.3 Global Inhalation Anaesthesia Market (2017-2032) by Region
- 7.3.1 Market Overview
- 7.3.2 North America
- 7.3.3 Europe
- 7.3.4 Asia Pacific
- 7.3.5 Latin America
- 7.3.6 Middle East and Africa
- 8 North America Inhalation Anaesthesia Market (2017-2032)
- 8.1 North America Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 8.1.1 Market Overview
- 8.1.2 Sevoflurane
- 8.1.3 Desflurane
- 8.1.4 Isoflurane
- 8.1.5 Halothane
- 8.2 North America Inhalation Anaesthesia Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Induction
- 8.2.3 Maintenance
- 8.3 North America Inhalation Anaesthesia Market (2017-2032) by Country
- 8.3.1 United States of America
- 8.3.2 Canada
- 9 Europe Inhalation Anaesthesia Market (2017-2032)
- 9.1 Europe Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 9.1.1 Market Overview
- 9.1.2 Sevoflurane
- 9.1.3 Desflurane
- 9.1.4 Isoflurane
- 9.1.5 Halothane
- 9.2 Europe Inhalation Anaesthesia Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Induction
- 9.2.3 Maintenance
- 9.3 Europe Inhalation Anaesthesia Market (2017-2032) by Country
- 9.3.1 United Kingdom
- 9.3.2 Germany
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Others
- 10 Asia Pacific Inhalation Anaesthesia Market (2017-2032)
- 10.1 Asia Pacific Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 10.1.1 Market Overview
- 10.1.2 Sevoflurane
- 10.1.3 Desflurane
- 10.1.4 Isoflurane
- 10.1.5 Halothane
- 10.2 Asia Pacific Inhalation Anaesthesia Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Induction
- 10.2.3 Maintenance
- 10.3 Asia Pacific Inhalation Anaesthesia Market (2017-2032) by Country
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 ASEAN
- 10.3.5 Australia
- 10.3.6 Others
- 11 Latin America Inhalation Anaesthesia Market (2017-2032)
- 11.1 Latin America Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 11.1.1 Market Overview
- 11.1.2 Sevoflurane
- 11.1.3 Desflurane
- 11.1.4 Isoflurane
- 11.1.5 Halothane
- 11.2 Latin America Inhalation Anaesthesia Market (2017-2032) by Application
- 11.2.1 Market Overview
- 11.2.2 Induction
- 11.2.3 Maintenance
- 11.3 Latin America Inhalation Anaesthesia Market (2017-2032) by Country
- 11.3.1 Brazil
- 11.3.2 Argentina
- 11.3.3 Mexico
- 11.3.4 Others
- 12 Middle East and Africa Inhalation Anaesthesia Market (2017-2032)
- 12.1 Middle East and Africa Inhalation Anaesthesia Market (2017-2032) by Drug Type
- 12.1.1 Market Overview
- 12.1.2 Sevoflurane
- 12.1.3 Desflurane
- 12.1.4 Isoflurane
- 12.1.5 Halothane
- 12.2 Middle East and Africa Inhalation Anaesthesia Market (2017-2032) by Application
- 12.2.1 Market Overview
- 12.2.2 Induction
- 12.2.3 Maintenance
- 12.3 Middle East and Africa Inhalation Anaesthesia Market (2017-2032) by Country
- 12.3.1 Saudi Arabia
- 12.3.2 United Arab Emirates
- 12.3.3 Nigeria
- 12.3.4 South Africa
- 12.3.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Clinical Trial Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Grant Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Product
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Type of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.1.1 Market Share Analysis: Global
- 19.1.2 Market Share Analysis: North America
- 19.1.3 Market Share Analysis: Europe
- 19.1.4 Market Share Analysis: Asia Pacific
- 19.1.5 Market Share Analysis: Others
- 19.2 Halocarbon Life Sciences, LLC .
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Mergers and Acquisitions
- 19.2.5 Certifications
- 19.3 Baxter International Inc
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Mergers and Acquisitions
- 19.3.5 Certifications
- 19.4 AbbVie Inc .
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Mergers and Acquisitions
- 19.4.5 Certifications
- 19.5 Sandoz AG
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Mergers and Acquisitions
- 19.5.5 Certifications
- 19.6 Piramal Enterprises Ltd .
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Mergers and Acquisitions
- 19.6.5 Certifications
- 19.7 Dechra Pharmaceuticals PLC
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Mergers and Acquisitions
- 19.7.5 Certifications
- 19.8 Fresenius Kabi AG
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Mergers and Acquisitions
- 19.8.5 Certifications
- 19.9 Hikma Pharmaceuticals PLC
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Mergers and Acquisitions
- 19.9.5 Certifications
- 19.10 Jiangsu Hengrui Medicine Co. Ltd
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Mergers and Acquisitions
- 19.10.5 Certifications
- 19.11 Lunan Pharmaceutical Group Co. Ltd
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Mergers and Acquisitions
- 19.11.5 Certifications
- 19.12 Merck KGaA
- 19.12.1 Financial Analysis
- 19.12.2 Product Portfolio
- 19.12.3 Demographic
- 19.12.4 Mergers and Acquisitions
- 19.12.5 Certifications
- 19.13 Troikaa Pharmaceuticals Ltd
- 19.13.1 Financial Analysis
- 19.13.2 Product Portfolio
- 19.13.3 Demographic Reach and Achievements
- 19.13.4 Mergers and Acquisitions
- 19.13.5 Certifications
- 20 Inhalation Anaesthesia Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom request.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.